lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly stock jumps on

If you microdose retatrutide and lose the glucagon component, you might go from 24% weight loss to 15% weight loss, essentially converting your triple agonist into a less efficient version of what you could get from semaglutide alone

Several factors are actively working to degrade your peptide, and understanding them is the first step toward neutralizing them

Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, Wada H, Hasegawa K, Shimatsu A, Satoh-Asahara N

Although we love to see you in person, we understand that some patients may live farther away and cant always make the drive to Lawrence or Leawood to see us

Dose level matters because most programs price by dose tier

It was discontinued in 2008 due to manufacturing issues (not safety concerns) and is still available through compounding pharmacies